1346233-68-8
1346233-68-8 structure
- Name: ML218
- Chemical Name: 3,5-Dichloro-N-{[(1R,5S)-3-(3,3-dimethylbutyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl}benzamide hydrochloride (1:1)
- CAS Number: 1346233-68-8
- Molecular Formula: C19H26Cl2N2O
- Molecular Weight: 369.33
- Catalog: Signaling Pathways Membrane Transporter/Ion Channel Calcium Channel
- Create Date: 2018-03-12 11:26:51
- Modify Date: 2024-01-14 14:34:13
-
ML218 is a selective T-type calcium channel inhibitor with IC50s of 270 and 310 nM for Cav3.3 and Cav3.2 in electrophysiology assay, respectively.
| Name | 3,5-Dichloro-N-{[(1R,5S)-3-(3,3-dimethylbutyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl}benzamide hydrochloride (1:1) |
|---|---|
| Synonyms |
Benzamide, 3,5-dichloro-N-[[(1R,5S)-3-(3,3-dimethylbutyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]-, hydrochloride (1:1)
3,5-Dichloro-N-{[(1R,5S)-3-(3,3-dimethylbutyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl}benzamide hydrochloride (1:1) ML218 |
| Description | ML218 is a selective T-type calcium channel inhibitor with IC50s of 270 and 310 nM for Cav3.3 and Cav3.2 in electrophysiology assay, respectively. |
|---|---|
| Related Catalog | |
| Target |
IC50: 270 nM (Cav3.3), 310 nM (Cav3.2)[1] |
| In Vitro | ML218 (CID 45115620) inhibits Cav3.1, Cav3.2, Cav3.3[1]. |
| In Vivo | Electrophysiology studies in STN neurons demonstrate robust effects of ML218 on the inhibition of T-type calcium current, inhibition of low threshold spike, and rebound burst activity. ML218 was found to be orally efficacious in a dose-dependent manner in a preclinical Parkinson’s disease model, haloperidol-induced catalepsy, and comparable to clinically validated A2A antagonism[1]. ML218 reaches a peak cerebrospinal fluid concentration 1-2 hrs after s.c. administration. No effects of ML218 on cardiac rhythmicity is found in electrocardiographic studies. ML218 does not have antiparkinsonian effects in MPTP-treated parkinsonian monkeys, due at least in part, to the agent’s sedative effects[2]. |
| Animal Admin | Rats: ML218 is administered intravenously (IV) to rats via the jugular vein catheter in 20% DMSO/80% saline at a dose of 1 mg/kg and a dose volume of 1 mL/kg. Blood collections via the carotid artery are performed at predose, and at 2 min, 7 min, 15 min, 30 min, and 1 h, 2 h, 4 h, 7 h, and 24 h post dose. Samples are collected into chilled, EDTA-fortified tubes, and centrifuged for 10 min at 3000 rpm (4°C), and resulting plasma is aliquoted into 96-well plates for LC/MS/MS analysis. For oral exposure studies, measuring both systemic plasma and CNS tissue exposure, ML218 is administered (oral gavage) to fasted rats as suspensions in 10% Tween 80/0.5% methylcellulose at a dose of 10 mg/kg and in a dosing volume of 10 mL/kg; blood and whole brain samples are collected at 1.5 h post dose. Blood is collected into chilled, EDTA-fortified tubes, centrifuged for 10 min at 3000 rpm (4°C), and stored at −80 °C until LC/MS/MS analysis[1]. |
| References |
| Molecular Formula | C19H26Cl2N2O |
|---|---|
| Molecular Weight | 369.33 |
| RIDADR | NONH for all modes of transport |
|---|